全文获取类型
收费全文 | 2338598篇 |
免费 | 174969篇 |
国内免费 | 3286篇 |
专业分类
耳鼻咽喉 | 32035篇 |
儿科学 | 75831篇 |
妇产科学 | 62660篇 |
基础医学 | 347383篇 |
口腔科学 | 63564篇 |
临床医学 | 210372篇 |
内科学 | 454294篇 |
皮肤病学 | 51698篇 |
神经病学 | 184905篇 |
特种医学 | 87936篇 |
外国民族医学 | 489篇 |
外科学 | 353336篇 |
综合类 | 47312篇 |
现状与发展 | 12篇 |
一般理论 | 848篇 |
预防医学 | 181745篇 |
眼科学 | 54159篇 |
药学 | 174864篇 |
9篇 | |
中国医学 | 4573篇 |
肿瘤学 | 128828篇 |
出版年
2021年 | 18810篇 |
2019年 | 19533篇 |
2018年 | 27050篇 |
2017年 | 20355篇 |
2016年 | 22744篇 |
2015年 | 25638篇 |
2014年 | 36096篇 |
2013年 | 53951篇 |
2012年 | 74675篇 |
2011年 | 79407篇 |
2010年 | 47058篇 |
2009年 | 44564篇 |
2008年 | 74608篇 |
2007年 | 79476篇 |
2006年 | 80294篇 |
2005年 | 77777篇 |
2004年 | 74365篇 |
2003年 | 71689篇 |
2002年 | 69362篇 |
2001年 | 108737篇 |
2000年 | 111450篇 |
1999年 | 93494篇 |
1998年 | 26990篇 |
1997年 | 23658篇 |
1996年 | 24054篇 |
1995年 | 22714篇 |
1994年 | 20763篇 |
1993年 | 19593篇 |
1992年 | 71871篇 |
1991年 | 70045篇 |
1990年 | 68347篇 |
1989年 | 65624篇 |
1988年 | 60245篇 |
1987年 | 59075篇 |
1986年 | 55181篇 |
1985年 | 52965篇 |
1984年 | 39235篇 |
1983年 | 33299篇 |
1982年 | 19758篇 |
1979年 | 35782篇 |
1978年 | 25577篇 |
1977年 | 21129篇 |
1976年 | 20254篇 |
1975年 | 21752篇 |
1974年 | 26089篇 |
1973年 | 24761篇 |
1972年 | 23179篇 |
1971年 | 22013篇 |
1970年 | 20220篇 |
1969年 | 19285篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
43.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
44.
45.
46.
Samir Gupta MD MDCS AGAF Balambal Bharti MBBS MPH PhD Dennis J. Ahnen MD Daniel D. Buchanan PhD Iona C. Cheng PhD MPH Michelle Cotterchio PhD Jane C. Figueiredo PhD Steven J. Gallinger MD MSc Robert W. Haile DrPH MPH Mark A. Jenkins PhD Noralane M. Lindor MD Finlay A. Macrae MD AGAF Loïc Le Marchand MD PhD Polly A. Newcomb PhD MPH Stephen N. Thibodeau PhD Aung Ko Win MBBS MPH PhD Maria Elena Martinez PhD 《Cancer》2020,126(13):3013-3020
47.
Candayan Ayşe Yunisova Gulshan Çakar Arman Durmuş Hacer Başak A. Nazlı Parman Yeşim Battaloğlu Esra 《Neurogenetics》2020,21(1):73-78
neurogenetics - Charcot-Marie-Tooth (CMT) disease is the most common inherited neuropathy with a prevalence of 1 in 2500 individuals worldwide. Here, we report three Turkish siblings from... 相似文献
48.
Key Jana Maletzko Antonia Kohli Aneesha Gispert Suzana Torres-Odio Sylvia Wittig Ilka Heidler Juliana Bárcena Clea López-Otín Carlos Lei Yuanjiu West A. Phillip Münch Christian Auburger Georg 《Neurogenetics》2020,21(3):187-203
neurogenetics - Human RNF213, which encodes the protein mysterin, is a known susceptibility gene for moyamoya disease (MMD), a cerebrovascular condition with occlusive lesions and compensatory... 相似文献
49.
Vilma Liaugaudaite Naomi A. Fineberg Aurelija Podlipskyte Julija Gecaite Alicja Juskiene Narseta Mickuviene 《International journal of psychiatry in clinical practice》2020,24(2):116-119
AbstractObjective: This study aims at identifying associations between cognitive function and suicidal ideation in the sample of patients with anxiety and mood disorders (AMD).Methods: In sum, 186 (age = 39?±?12.3 years; 142 [76.3%] females) patients with AMD were enrolled in the study. Assessment included evaluation of socio-demographic information, medication use, anxiety and depression symptoms. Cognitive tests included measures of psychomotor performance and incidental learning using the Digit Symbol Test. Trail Making Tests respectively measured perceptual speed, task-switching and executive control. Additionally, 21 patients completed tests from the Cambridge Automated Neuropsychological Test Battery measuring set shifting (Interdimensional/extradimensional set-shift), executive planning (Stockings of Cambridge), and decision making (Cambridge Gamble Task [CGT]).Results: Almost half (45.0%, n?=?86) of the study sample patients had experienced suicidal ideations. In multivariable regression analysis, suicidal ideation was associated with a greater overall proportion of bet and risk taking on the CGT task (β?=?0.726, p?=?.010 and β?=?0.634, p?=?.019), when controlling for socio-demographic characteristics, medication use, anxiety and depression symptoms.Conclusions: Outpatients with AMD and suicidal ideation could be distinguished by the presence of cognitive deficits in the executive function domain, particularly in impulse-control and risk taking. 相似文献
50.